Revvity Inc. stock gains momentum as UBS adjusts price target and Q2 2026 revenue edges higher
Published on 09/11/2026 at 13:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Revvity Inc. stock (ISIN US76155R1086) closed at USD 121.03 on the New York Stock Exchange on September 10, 2026, leaving the shares about 9.1 percent below their 52-week high of USD 133.00 in a market that has seen the stock gain 25.0 percent year to date from USD 96.81 at the start of 2026. As MarketBeat reported on September 10, 2026, UBS recently downgraded Revvity from Buy to Neutral while raising its price target from USD 120 to USD 140, underscoring a more cautious stance after a strong run in the shares.
Q2 2026 revenue edges higher with modest growth
According to StockTitan, Revvity reported second-quarter 2026 revenue of USD 729.7 million, up about 1 percent compared with USD 720.3 million in the same quarter of 2025, signaling a period of moderate top-line expansion as the company digests past portfolio changes. The same filing shows that for the first six months of 2026, revenue reached USD 1.44 billion versus USD 1.39 billion in the prior-year period, implying an increase of roughly USD 50 million or about 3.6 percent year on year and highlighting that growth accelerated slightly on a half-year basis compared with the single-digit quarterly gain.
In addition to the second-quarter figures, the 10-Q summary cited by StockTitan notes that Revvity generated first-quarter 2026 revenue of USD 711.1 million, up 7 percent from USD 664.8 million a year earlier, with both Life Sciences and Diagnostics contributing and an extra fiscal week supporting growth. For investors, this pattern means that while Q2 2026 growth slowed to around 1 percent, the combined first half still shows mid-single-digit expansion, suggesting a company navigating a more mature growth phase rather than a sharp slowdown.
Analyst actions and momentum ratings frame expectations
The UBS move has been a key catalyst in the latest discussion around Revvity Inc. stock because the bank shifted its rating to Neutral while simultaneously increasing the price target by USD 20 to USD 140, indicating that the upside from current levels appears more limited after the recent rally. As MarketBeat highlighted on September 9, 2026, this adjustment reflects a balancing act between acknowledging the companys operational execution and recognizing valuation constraints following a near 25 percent share-price gain since the start of the year.
Momentum-oriented analysis still paints an encouraging picture for Revvity. Zacks Investment Research noted on September 10, 2026, that Revvity carries a Zacks Rank of 3 (Hold) with a Momentum Style Score of A, with shares up 5.1 percent over the past four weeks and an average earnings surprise of 6.6 percent, while the consensus earnings estimate for fiscal 2026 has risen by USD 0.08 to USD 5.36 per share over the past 60 days. From a quantitative perspective, this combination of upward revisions and positive earnings surprises supports the view that Revvity Inc. stock has benefited from a constructive earnings backdrop even as some analysts grow more cautious on valuation.
Acquisition plans and strategic positioning support the story
Beyond quarterly numbers and ratings, Revvity has also been active on the strategic front. As MarketBeat relayed on September 9, 2026, a BusinessWire release announced that Revvity plans to acquire Human Cell Design to advance human-relevant cell models for metabolic disease drug discovery, underlining the companys push to strengthen its life sciences tools portfolio. Strategically, folding in specialized cell-model capabilities can help Revvity deepen its offering to pharmaceutical and biotech customers, potentially supporting higher-value solutions and reinforcing recurring revenue streams over time.
The acquisition plan also points to a key risk factor: every new deal comes under closer scrutiny when a stock already trades near the upper end of its recent range. A commentary cited by Simply Wall St noted that Revvity recently closed at USD 123.85, marginally above one widely followed fair-value estimate of around USD 121.07, suggesting that investors are carefully evaluating whether acquisitions like Human Cell Design can deliver the synergies needed to justify current valuations.
Stock remains below recent high but shows strong year-to-date gains
Per data from a major US stock portal, Revvity Inc. stock finished regular trading at USD 121.03 on the New York Stock Exchange on September 10, 2026, down 2.27 percent or USD 2.82 from the prior close of USD 123.85, with after-hours trading indicating a further slight dip to USD 120.73. At that closing level, the shares remain 9.07 percent below the 52-week high of USD 133.00 reached on September 3, 2026, while still up 25.0 percent year to date compared with the opening level of USD 96.81 on January 1, 2026, leaving Revvity Inc. stock positioned as a notable outperformer versus the broader market despite the recent pullback.
Key data on Revvity Inc. stock
- Company: Revvity Inc.
- ISIN: US76155R1086
- Ticker: RVTY
- Trading venue: NYSE
- Price (as of September 10, 2026, 03:59): 121.03 USD
- Market capitalization: 15,000,000,000 USD (as of September 10, 2026)
- Sector / Industry: Health Care / Life Sciences Tools and Services
- Index membership: S and P 500
